CureVac (NASDAQ:CVAC) | Finanzwire

Basculer en Français

10189	Companies
209749	Keywords
139909	Articles
111226	Press releases

Home
Companies
CureVac

PRESS RELEASE

published on 11/04/2024 at 13:03, 1 year 5 months ago

CureVac Strengthens Leadership Team with Appointment of Seasoned Industry Executive Axel Sven Malkomes as Chief Financial Officer
CureVac appoints Axel Sven Malkomes as CFO, bringing 30 years of industry experience. His role will drive strategic initiatives, financial foundation, and shareholder value

Biopharmaceutical Company CFO MRNA Technology CureVac Axel Sven Malkomes
PRESS RELEASE

published on 11/04/2024 at 13:00, 1 year 5 months ago

CureVac to Present at the 12th International mRNA Health Conference
CureVac to present new data at the 12th International mRNA Health Conference, showcasing developments in mRNA cancer vaccine and lipid nanoparticle delivery technology

Innovation Biopharmaceutical CureVac MRNA Platform MRNA Health Conference
BRIEF

published on 10/28/2024 at 13:05, 1 year 5 months ago

CureVac to Present New Findings at SITC Annual Meeting

Clinical Trials MRNA Technology Cancer Vaccine CureVac SITC Meeting
PRESS RELEASE

published on 10/28/2024 at 13:00, 1 year 5 months ago

CureVac to Present at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
CureVac to present at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting, sharing immunogenicity data on mRNA-based cancer vaccine CVGBM. Conference details and contact info provided

CureVac MRNA Poster Presentation Immunogenicity Society For Immunotherapy Of Cancer
BRIEF

published on 09/13/2024 at 14:02, 1 year 6 months ago

CureVac's CVGBM Cancer Vaccine Shows Promising Results in Phase 1 Glioblastoma Study

CureVac Glioblastoma CVGBM Phase 1 Study T-cell Responses
PRESS RELEASE

published on 09/13/2024 at 13:57, 1 year 6 months ago

CureVac’s CVGBM Cancer Vaccine Induces Promising Immune Responses in Phase 1 Study in Glioblastoma Presented at the ESMO 2024 Congress
CureVac's CVGBM Cancer Vaccine induces promising immune responses in Phase 1 Study in Glioblastoma presented at ESMO 2024 Congress. Results show de novo T-cell activity & acceptable safety profile up to 100 µg dose

Cancer Vaccine CureVac CVGBM Phase 1 Study Immune Responses
BRIEF

published on 09/12/2024 at 13:02, 1 year 6 months ago

CureVac and GSK Report Positive Phase 2 Data for Influenza mRNA Vaccine

MRNA Technology Influenza Vaccine Phase 2 Results GSK Partnership CureVac Milestone
PRESS RELEASE

published on 09/12/2024 at 12:57, 1 year 6 months ago

CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA Vaccine Program
CureVac Partner GSK reports positive Phase 2 results for seasonal influenza mRNA vaccine program. Data show immune responses to A and B strains with acceptable safety profile

GSK CureVac Phase 2 MRNA Vaccine Seasonal Influenza
BRIEF

published on 09/09/2024 at 13:05, 1 year 7 months ago

CureVac to Present First CVGBM Glioblastoma Cancer Vaccine Clinical Data at ESMO 2024 Congress

Clinical Data CureVac MRNA Vaccine Glioblastoma ESMO Congress
PRESS RELEASE

published on 09/09/2024 at 13:00, 1 year 7 months ago

CureVac to Present First CVGBM Glioblastoma Cancer Vaccine Clinical Data at ESMO 2024 Congress
CureVac to present first CVGBM Glioblastoma cancer vaccine clinical data at ESMO 2024 Congress. First-in-human study results to be shared, highlighting mRNA technology's potential for cancer vaccines

MRNA Technology CureVac Glioblastoma CVGBM ESMO 2024 Congress

Accesswire

Published on 04/11/2026 at 02:00, 21 hours 51 minutes ago

Lobe Sciences Ltd. Announces Non-Brokered Private Placement
Published on 04/11/2026 at 01:40, 22 hours 11 minutes ago

Arctic Fox Announces Closing of Final Tranche Of Non-Brokered Private Placement
Published on 04/11/2026 at 00:30, 23 hours 21 minutes ago

Trans Canada Gold Corp. Announces Proposed Warrant Extension
Published on 04/10/2026 at 23:30, 1 day ago

Clean Air Metals Announces Management Changes
Published on 04/10/2026 at 23:15, 1 day ago

Gemdale Announces Change of Corporate Secretary

View all ACCESSWIRE

EQS Group

Published on 04/11/2026 at 16:45, 7 hours 6 minutes ago

CGTN: One family: Xi Jinping stresses keeping future of cross-Strait ties in Chinese hands
Published on 04/11/2026 at 16:40, 7 hours 11 minutes ago

VARON Delivers Advanced Portable Oxygen Concentrator to Meet Rising Demand in Europe
Published on 04/11/2026 at 16:30, 7 hours 21 minutes ago

VARON Oxygen Concentrators Meet Rising Demand for Modern Oxygen Therapy in Germany
Published on 04/10/2026 at 19:00, 1 day 4 hours ago

EPIC Suisse AG – Annual General Meeting 2026 approves all proposals by the Board of Directors
Published on 04/10/2026 at 18:30, 1 day 5 hours ago

AGM 2026 - Bossard Holding AG Press Release

Les Echos

Published on 04/11/2026 at 16:29, 7 hours 22 minutes ago

Passing of Madame Jacqueline Himsworth, Chairman of the Board of Directors of Manitou Group
Published on 04/10/2026 at 18:35, 1 day 5 hours ago

Disclosure of trading own shares
Published on 04/10/2026 at 18:26, 1 day 5 hours ago

EURAZEO ANNOUNCES THE SUCCESS OF ITS INAUGURAL 500 MILLION EURO BOND ISSUE
Published on 04/10/2026 at 18:00, 1 day 5 hours ago

Declaration of voting rights at the end of March 2026
Published on 04/10/2026 at 17:45, 1 day 6 hours ago

Imerys-10-04-2026-implementation of the share buyback program

View all LES ECHOS COMFI WIRE